ArticleCommunications biology2020
NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors.
Romel Somwar et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
33 papers cite it
this papercites it